title: Debate: PCI vs CABG: a moving target, but we are gaining.
abstract: The treatment of patients with coronary artery disease continues to evolve; all three strategies - medical therapy, surgical revascularization, and percutaneous coronary intervention - have changed. Medical therapy with intense risk-factor modification and treatment with a statin, aspirin, and angiotensin-converting enzyme (ACE) inhibitors, should be used unless contraindicated. Surgical therapy has also changed with the introduction of minimally invasive, beating heart surgery. Percutaneous coronary intervention has perhaps changed the most radically with adjunctive therapy - glycoprotein IIb/IIIa inhibitors, thienopyridines, and reliance on stent implantation. The future, with new distal protection devices and drug-coated stents, should continue to see increased numbers of patients who can benefit from percutaneous intervention.
authors.affiliation: Mayo Clinic, Rochester, Minnesota, USA. holmes.david@mayo.edu
authors.forename: David R
authors.initials: DR
authors.lastname: Holmes